Use the journals feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
JOURNAL ARTICLE
(no author information available yet)
No abstract text is available yet for this article.
September 12, 2024: Diabetologia
#2
Rodolfo J Galindo, Diana Soliman, Daniel Cherñavvsky, Connie M Rhee
No abstract text is available yet for this article.
September 10, 2024: Diabetologia
#3
JOURNAL ARTICLE
Tsugumasa Toma, Nobukazu Miyakawa, Yuiichi Arakaki, Takuro Watanabe, Ryosei Nakahara, Taha F S Ali, Tanima Biswas, Mikio Todaka, Tatsuya Kondo, Mikako Fujita, Masami Otsuka, Eiichi Araki, Hiroshi Tateishi
AIMS/HYPOTHESIS: Appropriate management of blood glucose levels and the prevention of complications are important in the treatment of diabetes. We have previously reported on a compound named HPH-15 that is not only antifibrotic but also AMP-activated protein kinase (AMPK)-activating. In this study, we evaluated whether HPH-15 is useful as a therapeutic medication for diabetes. METHODS: We examined the effects of HPH-15 on AMPK activation, glucose uptake, fat accumulation and lactic acid production in L6-GLUT4, HepG2 and 3T3-L1 cells, as a model of muscle, liver and fat tissue, respectively...
September 9, 2024: Diabetologia
#4
JOURNAL ARTICLE
Nathalie Esser, Meghan F Hogan, Andrew T Templin, Rehana Akter, Brendy S Fountaine, Joseph J Castillo, Assam El-Osta, Lakshan Manathunga, Alexander Zhyvoloup, Daniel P Raleigh, Sakeneh Zraika, Rebecca L Hull, Steven E Kahn
AIMS/HYPOTHESIS: Apart from its fibrinolytic activity, the tissue plasminogen activator (tPA)/plasmin system has been reported to cleave the peptide amyloid beta, attenuating brain amyloid deposition in Alzheimer's disease. As aggregation of human islet amyloid polypeptide (hIAPP) is toxic to beta cells, we sought to determine whether activation of the fibrinolytic system can also reduce islet amyloid deposition and its cytotoxic effects, which are both observed in type 2 diabetes. METHODS: The expression of Plat (encoding tPA) and plasmin activity were measured in isolated islets from amyloid-prone hIAPP transgenic mice or non-transgenic control islets expressing non-amyloidogenic mouse islet amyloid polypeptide cultured in the absence or presence of the amyloid inhibitor Congo Red...
September 9, 2024: Diabetologia
#5
LETTER
Sigurd Lenzen
No abstract text is available yet for this article.
September 7, 2024: Diabetologia
#6
JOURNAL ARTICLE
Diana C Soria-Contreras, Siwen Wang, Jiaxuan Liu, Rebecca B Lawn, Makiko Mitsunami, Alexandra C Purdue-Smithe, Cuilin Zhang, Emily Oken, Jorge E Chavarro
AIMS/HYPOTHESIS: We aimed to determine whether a history of gestational diabetes mellitus (GDM) is associated with cognitive function in midlife. METHODS: We conducted a secondary data analysis of the prospective Nurses' Health Study II. From 1989 to 2001, and then in 2009, participants reported their history of GDM. A subset participated in a cognition sub-study in 2014-2019 (wave 1) or 2018-2022 (wave 2). We included 15,906 parous participants (≥1 birth at ≥18 years) who completed a cognitive assessment and were free of CVD, cancer and diabetes before their first birth...
September 6, 2024: Diabetologia
#7
JOURNAL ARTICLE
Nicholas A Wachowski, James A Pippin, Keith Boehm, Sumei Lu, Michelle E Leonard, Elisabetta Manduchi, Ursula W Parlin, Martin Wabitsch, Alessandra Chesi, Andrew D Wells, Struan F A Grant, Matthew C Pahl
AIMS/HYPOTHESIS: Genome-wide association studies (GWAS) have identified hundreds of type 2 diabetes loci, with the vast majority of signals located in non-coding regions; as a consequence, it remains largely unclear which 'effector' genes these variants influence. Determining these effector genes has been hampered by the relatively challenging cellular settings in which they are hypothesised to confer their effects. METHODS: To implicate such effector genes, we elected to generate and integrate high-resolution promoter-focused Capture-C, assay for transposase-accessible chromatin with sequencing (ATAC-seq) and RNA-seq datasets to characterise chromatin and expression profiles in multiple cell lines relevant to type 2 diabetes for subsequent functional follow-up analyses: EndoC-BH1 (pancreatic beta cell), HepG2 (hepatocyte) and Simpson-Golabi-Behmel syndrome (SGBS; adipocyte)...
September 6, 2024: Diabetologia
#8
LETTER
Jan W Eriksson, Maria J Pereira, Giovanni Fanni, Ulf Risérus, Mark Lubberink, Håkan Ahlström
No abstract text is available yet for this article.
September 5, 2024: Diabetologia
#9
LETTER
Roy Taylor
No abstract text is available yet for this article.
September 5, 2024: Diabetologia
#10
LETTER
Decio L Eizirik, Priscila L Zimath, Xiaoyan Yi, Arturo Roca Rivada, Sarah J Richardson
No abstract text is available yet for this article.
September 5, 2024: Diabetologia
#11
Moshe Phillip, Peter Achenbach, Ananta Addala, Anastasia Albanese-O'Neill, Tadej Battelino, Kirstine J Bell, Rachel E J Besser, Ezio Bonifacio, Helen M Colhoun, Jennifer J Couper, Maria E Craig, Thomas Danne, Carine de Beaufort, Klemen Dovc, Kimberly A Driscoll, Sanjoy Dutta, Osagie Ebekozien, Helena Elding Larsson, Daniel J Feiten, Brigitte I Frohnert, Robert A Gabbay, Mary P Gallagher, Carla J Greenbaum, Kurt J Griffin, William Hagopian, Michael J Haller, Christel Hendrieckx, Emile Hendriks, Richard I G Holt, Lucille Hughes, Heba M Ismail, Laura M Jacobsen, Suzanne B Johnson, Leslie E Kolb, Olga Kordonouri, Karin Lange, Robert W Lash, Åke Lernmark, Ingrid Libman, Markus Lundgren, David M Maahs, M Loredana Marcovecchio, Chantal Mathieu, Kellee M Miller, Holly K O'Donnell, Tal Oron, Shivajirao P Patil, Rodica Pop-Busui, Marian J Rewers, Stephen S Rich, Desmond A Schatz, Rifka Schulman-Rosenbaum, Kimber M Simmons, Emily K Sims, Jay S Skyler, Laura B Smith, Cate Speake, Andrea K Steck, Nicholas P B Thomas, Ksenia N Tonyushkina, Riitta Veijola, John M Wentworth, Diane K Wherrett, Jamie R Wood, Anette-Gabriele Ziegler, Linda A DiMeglio
No abstract text is available yet for this article.
September 4, 2024: Diabetologia
#12
JOURNAL ARTICLE
Rebecca L Thomson, James D Brown, Helena Oakey, Kirsten Palmer, Pat Ashwood, Megan A S Penno, Kelly J McGorm, Rachel Battersby, Peter G Colman, Maria E Craig, Elizabeth A Davis, Tony Huynh, Leonard C Harrison, Aveni Haynes, Richard O Sinnott, Peter J Vuillermin, John M Wentworth, Georgia Soldatos, Jennifer J Couper
AIMS/HYPOTHESIS: Dietary patterns characterised by high intakes of vegetables may lower the risk of pre-eclampsia and premature birth in the general population. The effect of dietary patterns in women with type 1 diabetes, who have an increased risk of complications in pregnancy, is not known. The aim of this study was to investigate the relationship between dietary patterns and physical activity during pregnancy and maternal complications and birth outcomes in women with type 1 diabetes...
September 2, 2024: Diabetologia
#13
JOURNAL ARTICLE
Fidelma Dunne, Christine Newman, Alberto Alvarez-Iglesias, Paula O'Shea, Declan Devane, Paddy Gillespie, Aoife Egan, Martin O'Donnell, Andrew Smyth
AIMS/HYPOTHESIS: Gestational diabetes mellitus (GDM) is associated with adverse perinatal outcomes because of suboptimal glucose management and glucose control and excessive weight gain. Metformin can offset these factors but is associated with small for gestational age (SGA) infants. We sought to identify risk factors for SGA infants, including the effect of metformin exposure on SGA status. METHODS: In this prespecified secondary analysis of the EMERGE trial, which evaluated the effectiveness of metformin vs placebo in treating GDM and found reduced gestational weight gain and longer time to insulin initiation with metformin use, we included women with a live-born infant and known infant birthweight and gestational age at delivery...
August 31, 2024: Diabetologia
#14
EDITORIAL
Ritwika Mallik, Partha Kar, Hindrik Mulder, Anna Krook
No abstract text is available yet for this article.
August 30, 2024: Diabetologia
#15
LETTER
Renza Scibilia, Niki Breslin-Brooker, Chris Bright, Tinotenda Dzikiti, Salih Hendricks, Vilgot Shik, Jazz Sethi, Sara Vanhentenryk, Lakshminarayana Varimadugu, Jurgen Vercauteren
No abstract text is available yet for this article.
August 30, 2024: Diabetologia
#16
JOURNAL ARTICLE
Donna S-H Lin, Jen-Kuang Lee, Kuan-Chih Huang, Ting-Tse Lin, Hao-Yun Lo
AIMS/HYPOTHESIS: Although the benefits of sodium-glucose cotransporter 2 inhibitor (SGLT2i) use in chronic kidney disease (CKD) are well established, the effects of these therapeutic agents in patients with advanced CKD are less certain. We hypothesised that the continued use of these drugs, even when renal function deteriorates to stage 4 CKD or worse, is safe and associated with improved cardiorenal survival. METHODS: This is a retrospective cohort study utilising data from medical records from two institutions...
August 29, 2024: Diabetologia
#17
JOURNAL ARTICLE
William L Lowe, Alan Kuang, M Geoffrey Hayes, Marie-France Hivert, Denise M Scholtens
AIMS/HYPOTHESIS: Pregnancy is accompanied by maternal metabolic adaptations to ensure fetal growth and development, including insulin resistance, which occurs primarily during the second and third trimesters of pregnancy, and a decrease in fasting blood sugar levels over the course of pregnancy. Glucose-related traits are regulated by genetic and environmental factors and modulated by physiological variations throughout the life course. We addressed the hypothesis that there are both overlaps and differences between genetic variants associated with glycaemia-related traits during and outside of pregnancy...
August 24, 2024: Diabetologia
#18
REVIEW
Lianna W Wat, Katrin J Svensson
The tight regulation of glucose and lipid metabolism is crucial for maintaining metabolic health. Dysregulation of these processes can lead to the development of metabolic diseases. Secreted factors, or hormones, play an essential role in the regulation of glucose and lipid metabolism, thus also playing an important role in the development of metabolic diseases such as type 2 diabetes and obesity. Given the important roles of secreted factors, there has been significant interest in identifying new secreted factors and new functions for existing secreted factors that control glucose and lipid metabolism...
August 24, 2024: Diabetologia
#19
JOURNAL ARTICLE
Gian Paolo Fadini, Enrico Longato, Mario Luca Morieri, Enzo Bonora, Agostino Consoli, Bruno Fattor, Mauro Rigato, Federica Turchi, Stefano Del Prato, Angelo Avogaro, Anna Solini
AIMS/HYPOTHESIS: We compared the effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) on renal outcomes in individuals with type 2 diabetes, focusing on the changes in eGFR and albuminuria. METHODS: This was a multicentre retrospective observational study on new users of diabetes medications. Participant characteristics were assessed before and after propensity score matching. The primary endpoint, change in eGFR, was analysed using mixed-effects models...
August 23, 2024: Diabetologia
#20
JOURNAL ARTICLE
Hayato Tanabe, Masahiro Sato, Akimitsu Miyake, Yoshinori Shimajiri, Takafumi Ojima, Akira Narita, Haruka Saito, Kenichi Tanaka, Hiroaki Masuzaki, Junichiro J Kazama, Hideki Katagiri, Gen Tamiya, Eiryo Kawakami, Michio Shimabukuro
AIMS/HYPOTHESIS: Clustering-based subclassification of type 2 diabetes, which reflects pathophysiology and genetic predisposition, is a promising approach for providing personalised and effective therapeutic strategies. Ahlqvist's classification is currently the most vigorously validated method because of its superior ability to predict diabetes complications but it does not have strong consistency over time and requires HOMA2 indices, which are not routinely available in clinical practice and standard cohort studies...
August 21, 2024: Diabetologia
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
